INDEPENDENT STUDY OF OVARIAN CANCER CTCS HARVESTED BY THE PARSORTIX SYSTEM HIGHLIGHTS POTENTIAL TO PREDICT PROGRESSION FREE SURVIVAL FOR DRUG TRIALS The study investigated 123 metastatic ovarian ...

GUILDFORD, UK / ACCESSWIRE / September 28, 2022 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the University of Birmingham has ...

DUBLIN and CHICAGO - May 3, 2016 - Medtronic plc (MDT) today announced results of seven-year follow-up data demonstrating favorable clinical outcomes and patient satisfaction for the 2-level Prestige ...

GUILDFORD, SURREY / ACCESS Newswire / July 8, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research ...

Haleon PLC ($GB:HLN) announced an update on their ongoing clinical study. Haleon PLC (GB:HLN) is conducting a decentralised, real-world study ...

DUBLIN and MUNICH - August 28, 2018 - Medtronic plc (NYSE:MDT) today announced new findings from the CRYO4PERSISTENT AF clinical trial demonstrating improved quality of life, reduced symptoms from ...

Indivior PLC ($INDV) announced an update on their ongoing clinical study. Indivior PLC recently completed a Phase II clinical study titled ‘A ...

ANGLE plc STUDY USING PARSORTIX DEMONSTRATES IMPORTANCE OF BIOMARKER-INDEPENDENT CTC ISOLATION IN HEAD AND NECK CANCER EMT status of CTCs found to provide additional insight to tumour tissue biopsy ...